ATTO News
Archived Headlines
- Immune-focused biotech Attovia Therapeutics ups deal size by 45%, sets proposed price at $17 ahead of $289 million IPO 08/04/26
- US IPO Week Ahead: August IPO market opens with biotechs, a bank, and SpaceX earnings 07/31/26
- Phase 1 immune system diseases biotech Attovia Therapeutics sets terms for $200 million IPO 07/29/26
- US IPO Weekly Recap: Csquare and Standard Nuclear both underwhelm amid cautious market 07/17/26
- Phase 1 immune system diseases biotech Attovia Therapeutics files for a $100 million IPO 07/14/26
Renaissance Capital’s August IPO Market Update
Ten IPOs raised a combined $1.8 billion in August, joined by two direct listings. Activity slowed from July’s pace as the market entered its typical summer slowdown but was slightly above the month’s 10-year historical average (10 IPOs, $1.7B). Six...read more
IPO Winners & Losers: New Stocks Surge, Biotech Booms, and AI Rallies
Welcome back to Renaissance Capital’s IPO Winners and Losers, the weekly podcast breaking down the biggest stories shaping the IPO market. Click here to get the newsletter in your inbox every week.
...read moreUS IPO Weekly Recap: August kicks off with flurry of biotech IPOs
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
Immune-focused biotech Attovia Therapeutics prices previously upsized IPO at $17, as expected
Attovia Therapeutics, a Phase 1 biotech developing biotherapeutics for immune-mediated diseases, raised $289 million by offering 17 million shares at $17, as expected. The company originally filed to offer 12.5 million shares at a range of $15 to $17, before it ...read more